Earlier today the FDA granted the Breakthrough Therapy Designation to venetoclax (ABT-199). Venetoclax was awarded this designation for the treatment of relapsed or refractory CLL in previously treated patients with 17p deletion. Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein.
The Breakthrough Therapy Designation is intended to expedite the development and review of drugs for life-threatening conditions, based on preliminary clinical evidence. A full list of targeted treatments that have received FDA approval for the treatment of lymphoma can be found here.
Currently the Lymphoma Program has several phase 2 trials open to accrual for ABT-199 as a treatment for CLL patients. Dr. Richard Furman is the principal investigator for both trials:
Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy
Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
A full listing of available CLL trials can be found here. Look to this space for more information regarding developments for the treatment of CLL.
One thought on “FDA Grants Breakthrough Therapy Designation to Venetoclax for Patients with Relapsed/Refractory CLL with 17p Deletion”
Thanks for posting this!